The Indian government has announced a cap on trade margins for all non‑scheduled anti‑cancer drugs, limiting them to 30% of the maximum retail price (MRP). The measure is expected to cover 110 medicines, including 35 patented drugs, and is slated for implementation later this month. The decision, made by the Department of Pharmaceuticals, aims to make cancer treatment more affordable, potentially reducing medicine prices by up to 70% and saving cancer patients ₹2,500 crore annually. An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be covered under the cap.

Shares of key pharma and hospital stocks surged on Friday, October 9, as uncertainty eased following the announcement. Sun Pharmaceutical, Dr Reddy’s Laboratories, Max Healthcare Institute, Fortis Healthcare, Apollo Hospitals, and Global Health (Medanta) all experienced gains. The Nifty Healthcare index rose 1.3%, touching an intraday high of 15,902.45 points, up from 15,684.65 points at the previous close. The rally reflected investor optimism that the cap would benefit patients while the short‑term impact on company margins would be manageable.

Fortis Healthcare led the gains with an intraday high of ₹806, up 5.6%, while Apollo Hospitals reached ₹7,985, up 4.1%. Glenmark Pharma hit ₹2,274, up 3.7%; KIMS rose to ₹714.90, up 4%; and Max Healthcare peaked at ₹917.05, up 4.9%. Dr Reddy’s climbed to ₹1,196, up 1.3%; Lupin reached ₹1,968.90, up 1.6%; and Sun Pharma closed at ₹1,776.80, up 1%. These figures were sourced from the NSE website as of Friday, October 9, 2026.

The trade margin cap is expected to have a transitory negative effect on pharmaceutical companies that sell high‑priced anti‑cancer drugs with large trade margins. Analysts from Jefferies anticipate that near‑term margins will be impacted but that the effect will be manageable. The impact on individual stocks will depend on the proportion of revenue derived from affected medicines and the margins earned through the distribution chain.

Goldman Sachs analysts noted that hospitals could offset losses through marginal repricing of services such as drug administration charges, as hospitals reportedly earn a margin of 30‑50% on average on oncology drugs. The decision extends price protection to non‑scheduled cancer medicines, complementing existing strict ceiling prices for scheduled essential medicines.

The cap on trade margins is projected to reduce medicine prices by up to 70% and help cancer patients save ₹2,500 crore annually, according to the Department of Pharmaceuticals’ official announcement. The measure is expected to be implemented later this month, with the DGHS committee finalising the list of covered medicines. The announcement has lifted investor sentiment in the healthcare sector, leading to a rally in pharma and hospital stocks on October 9.